Turkoz I, Daly E, Singh J, et al. - Researchers investigated how patients with major depressive disorder (DSM-5) and treatment-resistant depression (TRD), who did not meet response criteria within the first week of treatment, respond to esketamine nasal spray plus an oral antidepressant (ESK + AD) at day 28. In the current study, they conducted a pooled post hoc analysis of two phase 3, double-blind, active-controlled studies comparing ESK + AD with an oral antidepressant plus placebo (AD + PBO). Per outcomes, a full 4-week induction course of esketamine nasal spray may be beneficial for patients with TRD without an established response within the first week of treatment.